Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CliniMACS CD34+ Enriched Transplants for Myelodysplastic Syndrome
NCT05617625Phase 2Not yet recruiting
- Start
- Jan 2027
- Primary completion
- Jan 2034
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in myelodysplastic syndrome (MDS) and graft-versus-host disease (GVHD). Primary endpoint: Overall survival at 2 years. Planned start Jan 2027; status: not yet recruiting.
02
Conditions
myelodysplastic syndrome (MDS)graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT05617625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05617625.